

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Jinxin Fertility Group Limited**

**錦欣生殖醫療集團有限公司\***

*(Incorporated under the laws of the Cayman Islands with limited liability)*

**(Stock Code: 1951)**

## **VOLUNTARY ANNOUNCEMENT KEY OPERATING DATA FOR THE FOURTH QUARTER OF 2025**

This is a voluntary announcement made by Jinxin Fertility Group Limited (the “**Company**”) to keep the shareholders of the Company and potential investors informed of the latest business developments of the Company and its subsidiaries (the “**Group**”).

The board of directors (the “**Board**”) of the Company is pleased to announce that, through continuous efforts in implementing operational optimization initiatives, the Group achieved further improvement in the number of in vitro fertilization (“**IVF**”) treatment cycles for the fourth quarter of 2025 as compared to the third quarter of 2025. In particular, the Group’s business in the Greater China in 2025 has demonstrated its resilience and recovered to 2024 levels with a mere 0.4% decrease (between the full year of 2024 and the full year of 2025), despite having experienced a decrease of 8.0% during the first half of 2025 when compared to the first half of 2024.

For the year ended December 31, 2025, the Group saw a further narrowing in the decrease in the overall IVF treatment cycles from -5.2% (between the first three quarters of 2024 and the first three quarters of 2025) to -1.4% (between the full year of 2024 and the full year of 2025). Specifically, the number of IVF treatment cycles of the Group’s flagship hospital in Chengdu demonstrated significant improvement, having reversed a decrease of -1.9% for the first three quarters of 2025 to a year-on-year increase of 1.3% for the full year of 2025. Meanwhile, the decline in the number of IVF treatment cycles in the Greater Bay Area narrowed from -13.5% for the first three quarters of 2025 to -5.9% for the full year of 2025. In the Group’s overseas markets in United States and Laos, the decline in the number of IVF treatment cycles also narrowed from -10.8% for the first three quarters of 2025 to -6.9% for the full year of 2025.

The table below sets forth the number of IVF treatment cycles of the Group's in-network hospitals and by hospitals and clinics managed under invest-operate-transfer (“**IOT**”) agreements or management service agreements (“**MSA**”)<sup>1</sup> for the year ended December 31, 2025 and for the nine months ended September 30, 2025, with comparative figures for the corresponding periods in 2024:

Region	Number of IVF treatment cycles					
	For the year ended		Period-on-period changes	For the nine months ended		Period-on-period changes
	December 31, 2024	2025		September 30, 2024	2025	
Chengdu	13,884	14,070	1.3%	11,025	10,819	-1.9%
Greater Bay Area	5,769	5,428	-5.9%	4,473	3,869	-13.5%
Kunming and Wuhan	4,242	4,306	1.5%	3,216	3,243	0.8%
Oversea (United States and Laos <sup>Note</sup> )	4,548	4,235	-6.9%	3,481	3,104	-10.8%
<b>Total</b>	<b>28,443</b>	<b>28,039</b>	<b>-1.4%</b>	<b>22,195</b>	<b>21,035</b>	<b>-5.2%</b>

*Note:*

- (1) The Company has terminated its operations in Laos and the liquidation procedures have been completed as of the date of this announcement.

Looking forward to 2026 and beyond, the Group endeavors to persisting in sharpening its clinical efficacy, elevating patient care and service delivery, and accelerating the upgrade of its core reproductive technologies. The Group will continue to deepen its scientific research in reproductive medicine for clinical application, streamline patient services and digitalize the overall service experience. The Group looks to consolidate the regional market position of the Chengdu flagship hospital, and expedite capacity ramp-up and market penetration following the relocation of the Greater Bay Area new hospital. At the same time, the Company will closely monitor and swiftly respond to overseas regulatory changes to unlock incremental international growth. By fully capturing the tailwinds of China's fertility-support policies and broader industry momentum, the Company will reinforce its competitiveness, through the delivery of high quality reproductive health services and ultimately deliver sustained long-term returns to shareholders, and advance the high-quality development of the industry.

The Company wishes to provide the shareholders and potential investors of the Company with a business update and the information contained herein is based on a preliminary assessment of the Group and the information currently available to the Company and is not based on any figure or information which has been audited or reviewed by the auditor of the Company. The above figures contained in this announcement are for illustrative purposes only, and do not constitute forward-looking statements or profit numbers.

<sup>1</sup> *IOT/MSA institutions refer to hospitals and clinics controlled by the Group through discipline co-construction and cooperation agreements and management service agreements.*

**Shareholders and potential investors of the Company are reminded to rationally deal with any information not officially released by the Company, and shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Jinxin Fertility Group Limited**  
**Dong Yang**  
*Chief Executive Officer,  
Acting Chief Financial Officer  
and Executive Director*

Hong Kong, January 5, 2025

*As at the date of this announcement, the board of directors of the Company comprises Mr. Dong Yang, Ms. Lyu Rong and Dr. Geng Lihong, as executive Directors; Mr. Zhong Yong, as Chairman and non-executive Director, and Ms. Hu Zhe, Ms. Yan Xiaoqing and Mr. Chen Shuyun, as non-executive Directors; and Dr. Chong Yat Keung, Mr. Li Jianwei, Mr. Wang Xiaobo and Mr. Ye Changqing, as independent non-executive Directors.*

*\* For identification purposes only*